Pharmaceutical company Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) revealed on Monday the launch of a US initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of COVID-19.

This programme initiative includes the availability of special financial arrangements for hospitals and clinics in the US to help ensure supply during this unprecedented healthcare crisis, added the company.

Concurrently, the company has announced a national programme with infectious disease experts to provide information on the management of complicated respiratory infections resulting from the novel coronavirus, including secondary bacterial infections.

The company's potent antibiotic VIBATIV (telavancin) injection designed to treat serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA), is approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable.

According to the company, the special financial arrangements include extended payment terms for all direct account purchases of its VIBATIV antibiotic. This will provide health care facilities the flexibility to weather the uncertain economic environment, while still providing the potent antibiotic treatment patients need.